Marius Giurescu

1.1k total citations
26 papers, 501 citations indexed

About

Marius Giurescu is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Marius Giurescu has authored 26 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 7 papers in Molecular Biology and 6 papers in Genetics. Recurrent topics in Marius Giurescu's work include Cancer Treatment and Pharmacology (14 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Marius Giurescu is often cited by papers focused on Cancer Treatment and Pharmacology (14 papers), Chronic Lymphocytic Leukemia Research (6 papers) and Lymphoma Diagnosis and Treatment (5 papers). Marius Giurescu collaborates with scholars based in Germany, United States and United Kingdom. Marius Giurescu's co-authors include Krimo Bouabdallah, Franck Morschhauser, Umberto Vitolo, Kim Linton, Dominique Bron, Pier Luigi Zinzani, David Cunningham, Sarit Assouline, Igor Gorbatchevsky and Li Liu and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Marius Giurescu

25 papers receiving 494 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Marius Giurescu Germany	13	292	177	168	161	77	26	501
Louise Barys Switzerland	8	157 0.5×	328 1.9×	53 0.3×	80 0.5×	69 0.9×	12	575
Donald P. Lesslie United States	8	353 1.2×	397 2.2×	71 0.4×	58 0.4×	42 0.5×	11	687
Xueqian Gong United States	8	294 1.0×	304 1.7×	97 0.6×	98 0.6×	30 0.4×	16	581
Christopher Riley United States	8	177 0.6×	179 1.0×	101 0.6×	55 0.3×	26 0.3×	11	514
Ricardo Parrondo United States	15	255 0.9×	374 2.1×	102 0.6×	130 0.8×	26 0.3×	75	698
Bianca T. Hofmann Germany	13	246 0.8×	509 2.9×	103 0.6×	61 0.4×	58 0.8×	24	742
Lucia Trandafir Switzerland	11	247 0.8×	280 1.6×	61 0.4×	73 0.5×	37 0.5×	22	634
Jianning Yang United States	14	220 0.8×	320 1.8×	237 1.4×	254 1.6×	14 0.2×	29	693
T. Christopher Windham United States	7	177 0.6×	203 1.1×	61 0.4×	27 0.2×	69 0.9×	14	438
Zhimin Gu United States	12	169 0.6×	459 2.6×	95 0.6×	59 0.4×	57 0.7×	20	642

Countries citing papers authored by Marius Giurescu

Since Specialization

Citations

This map shows the geographic impact of Marius Giurescu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marius Giurescu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marius Giurescu more than expected).

Fields of papers citing papers by Marius Giurescu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marius Giurescu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marius Giurescu. The network helps show where Marius Giurescu may publish in the future.

Co-authorship network of co-authors of Marius Giurescu

This figure shows the co-authorship network connecting the top 25 collaborators of Marius Giurescu. A scholar is included among the top collaborators of Marius Giurescu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marius Giurescu. Marius Giurescu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Morschhauser, Franck, Krimo Bouabdallah, Dominique Bron, et al.. (2017). Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma. Annals of Oncology. 28(9). 2169–2178. 192 indexed citations

Dreyling, Martin, et al.. (2015). Abstract CT215: CHRONOS-1: Open-label, uncontrolled phase II trial of intravenous phosphatidylinositol-3 kinase alpha/delta inhibitor copanlisib in patients with relapsed, indolent Non-Hodgkin's lymphomas (iNHL). Cancer Research. 75(15_Supplement). CT215–CT215.

Teufel, Michael, Jean‐Luc Van Laethem, Hanno Riess, et al.. (2015). Abstract 5239: KRAS wild-type status as detected by circulating tumor DNA analysis may be a prognostic or predictive factor for clinical benefit in patients with unresectable, locally advanced or metastatic pancreatic cancer (PC) treated with the MEK inhibitor refametin. Cancer Research. 75(15_Supplement). 5239–5239. 2 indexed citations

Dreyling, Martin, David Cunningham, Krimo Bouabdallah, et al.. (2014). Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma. Blood. 124(21). 1701–1701. 16 indexed citations

Laethem, Jean‐Luc Van, Jacek Jassem, Volker Heinemann, et al.. (2014). Phase II study of refametinib (BAY 86-9766), an allosteric dual MEK 1/2 inhibitor, and gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer.. Journal of Clinical Oncology. 32(15_suppl). 4025–4025. 10 indexed citations

Dreyling, Martin, Pier Luigi Zinzani, Krimo Bouabdallah, et al.. (2014). 499 Phase 2a study of copanlisib, a novel phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. European Journal of Cancer. 50. 162–163. 1 indexed citations

Riess, Hanno, Jean‐Luc Van Laethem, Uwe M. Martens, et al.. (2014). Phase II study of the MEK inhibitor refametinib (BAY 86-9766) in combination with gemcitabine in patients with unresectable, locally advanced, or metastatic pancreatic cancer: Biomarker results.. Journal of Clinical Oncology. 32(15_suppl). 4129–4129. 3 indexed citations

Gauler, Thomas, Daniel C. Christoph, Norbert Frickhofen, et al.. (2013). Phase-I study of sagopilone in combination with cisplatin in chemotherapy-naive patients with metastasised small-cell lung cancer. European Journal of Cancer. 49(11). 2461–2468. 8 indexed citations

Dreyling, Martin, Franck Morschhauser, Dominique Bron, et al.. (2013). Preliminary Results Of a Phase II Study Of Single Agent Bay 80-6946, a Novel PI3K Inhibitor, In Patients With Relapsed/Refractory, Indolent Or Aggressive Lymphoma. Blood. 122(21). 87–87. 32 indexed citations

10.

Beer, Tomasz M., et al.. (2012). Phase II study of first-line sagopilone plus prednisone in patients with castration-resistant prostate cancer: a phase II study of the Department of Defense Prostate Cancer Clinical Trials Consortium. British Journal of Cancer. 107(5). 808–813. 12 indexed citations

11.

Rustin, Gordon, Nicholas Reed, Gordon C. Jayson, et al.. (2011). A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology. 22(11). 2411–2416. 23 indexed citations

12.

McMeekin, Scott, Ravi Patel, Claire F. Verschraegen, et al.. (2011). Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer. British Journal of Cancer. 106(1). 70–76. 12 indexed citations

13.

Divers, Stephen G., Louise Provencher, Shiuh‐Wen Luoh, et al.. (2010). Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy. Breast Cancer Research and Treatment. 123(3). 837–842. 15 indexed citations

14.

Beer, Tomasz M., et al.. (2009). Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 27(15_suppl). 5059–5059. 6 indexed citations

15.

Arnold, Dirk, Wieland Voigt, Philipp Kiewe, et al.. (2009). Weekly administration of sagopilone (ZK-EPO), a fully synthetic epothilone, in patients with refractory solid tumours: results of a phase I trial. British Journal of Cancer. 101(8). 1241–1247. 23 indexed citations

16.

Schmid, Peter, Philipp Kiewe, K. Possinger, et al.. (2009). Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors. Annals of Oncology. 21(3). 633–639. 30 indexed citations

17.

Klar, Ulrich, Jens Hoffmann, & Marius Giurescu. (2008). Sagopilone (ZK-EPO): from a natural product to a fully synthetic clinical development candidate. Expert Opinion on Investigational Drugs. 17(11). 1735–1748. 20 indexed citations

18.

Rustin, Gordon, Nicholas S. Reed, Gordon C. Jayson, et al.. (2007). Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer. Journal of Clinical Oncology. 25(18_suppl). 5527–5527. 16 indexed citations

19.

Schmid, Peter, Philipp Kiewe, Agnieszka Korfel, et al.. (2005). A phase I study of the novel, third generation epothilone ZK-EPO in patients with advanced solid tumors. Journal of Clinical Oncology. 23(16_suppl). 2051–2051. 30 indexed citations

20.

Helle, Svein Inge, W. Jonat, Marius Giurescu, et al.. (1998). Influence of treatment with onapristone on the IGF-system in breast cancer patients. The Journal of Steroid Biochemistry and Molecular Biology. 66(3). 159–163. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact